Use of insulin glargine throughout pregnancy in 102 women with type 1 diabetes

Diabetes and Metabolism

Volumn 36, Issue 3, 2010, Pages 209-212

  Lepercq, J ^a   Jacqueminet, S ^b   Hieronimus, S ^c   Timsit, J ^a   Grimaldi, A ^b  

^a AP HP ^*  (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

Glargine; Insulin; Pregnancy; Type 1 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C; INSULIN GLARGINE; ANTIDIABETIC AGENT; GLARGINE; INSULIN; LONG ACTING INSULIN;

ADULT; ARTICLE; BIRTH WEIGHT; CONGENITAL MALFORMATION; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LARGE FOR GESTATIONAL AGE; MAJOR CLINICAL STUDY; PREGNANCY; PREGNANCY OUTCOME; PREMATURE LABOR; SIDE EFFECT; STILLBIRTH; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 1; MULTICENTER STUDY; PREGNANCY IN DIABETICS; RETROSPECTIVE STUDY;

DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PREGNANCY; PREGNANCY IN DIABETICS; PREGNANCY OUTCOME; RETROSPECTIVE STUDIES; INSULIN, LONG-ACTING;

EID: 77953476420     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2009.11.008     Document Type: Article

References (13)

1. Wyatt J.W., Frias J.L., Hoyme H.E., Jovanovic L., Kaaja R., Brown F., et al. Congenital anomaly rate in offspring of mothers with diabetes treated with insulin lispro during pregnancy. Diabet Med 22 (2005) 803-807
2. Mathiesen E.R., Kinsley B., Amiel S.A., Heller S., McCance D., Duran S., et al. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care 30 (2007) 771-776
3. Hofmann T., Horstmann G., and Stammberger I. Evaluation of the reproductive toxicity and embryotoxicity of insulin glargine (LANTUS) in rats and rabbits. Int J Toxicol 21 (2002) 181-189
4. Pöyhönen-Alho M., Rönnemaa T., Saltevo J., Ekblad U., and Kaaja R.J. Use of insulin glargine during pregnancy. Acta Obstet Gynecol Scand 29 (2007) 1-4
5. Gallen I.W., Jaap A., Roland J.M., and Chirayath H.H. Survey of glargine use in 115 pregnant women with Type 1 diabetes. Diabet Med 25 (2008) 165-169
6. Di Cianni G., Torlone E., Lencioni C., Bonomo M., Di Benedetto A., Napoli A., et al. Perinatal outcomes associated with the use of glargine during pregnancy. Diabet Med 25 (2008) 993-996
7. Johansen K.S., and Hod M. Quality development in perinatal care: the OBSQID project. OBStetrical Quality Indicators and Data. Int J Gynaecol Obstet 64 (1999) 167-172
8. Lechat M.F., and Dolk H. Registries of congenital anomalies: EUROCAT. Environ Health Perspect 101 Suppl. 2 (1993) 153-157
9. Price N., Bartlett C., and Gillmer M.D. Use of insulin glargine during pregnancy: a case-control pilot study. BJOG 114 (2007) 453-457
10. Kurtzhals P., Schaffer L., Sorensen A., Kristensen C., Jonassen I., Schmid C., et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49 (2000) 999-1005
11. Pollex EK, Feig DS, Lubetsky A, Yip PM, Koren G. Insulin glargine safety in pregnancy: a transplacental transfer study. Diabetes Care 2010;33:29-33.
12. Diabetes and Pregnancy Group, France. French multicentric survey of outcome of pregnancy in women with pregestational diabetes. Diabetes Care 2003;26:2990-3.
13. Koren G., Pastuszack A., and Ito S. Drugs in pregnancy. N Engl J Med 338 (1998) 1128-1137